General InformationSTORM Therapeutics is a Boston-based biotech company founded in 2017 with approximately 100-150 employees developing RNA modification therapies for cancer and genetic diseases.
Funding & FinancialsThe company has raised over $100 million across multiple rounds, with Series B funding led by top-tier biotech and venture investors including Flagship Pioneering.
Leadership & TeamFounded by researchers from MIT and Harvard including Szabolcs Szenasi and other leading epitranscriptomics experts; CEO transitions and scientific advisory board include prominent figures in RNA biology.
Recent ActivityRecent focus includes advancing lead candidates in oncology and expanding their RNA modification platform technology to multiple therapeutic areas with ongoing clinical development programs.